BACKGROUND: Ketoconazole has the ability to lower serum testosterone to castrate level within 48 h. As the prostate is an androgen-dependent organ, we investigated the effect of the use of tamsulosin in combination with ketoconazole in cases of acute urinary retention (AUR) due to benign prostatic obstruction (BPO). METHODS: We recruited patients with AUR secondary to BPO but those with hepatic or renal impairment were excluded. Following urethral catheterization, the participants were randomized into two equal groups. The first group received tamsulosin (0.4 mg o.d.) and ketoconazole (200 mg t.d.s.) while the second one had tamsulosin and placebo. The drugs were maintained for 7 days and then the patients were put on trial without catheter (TWOC). The successful cases were assessed with peak flow rate (PFR) and the postvoid residual urine volume (PVRV) was also estimated. RESULTS: We included 106 men with a mean age of 64.1 ± 5.2 years and a mean prostate size of 61.6 ± 14.6 g in the two groups. The received medications were well tolerated by all patients and none of them had discontinued the prescribed drugs. The incidence of the successful TWOC was significantly higher in the combined treatment group (77.35%) compared to the tamsulosin group (58.84%; P ¼ 0.01). Among those who had a successful TWOC, the PFR and the PVRV were also significantly better in the combined treatment group compared to the other one (P ¼ 0.001). CONCLUSIONS: Patients with AUR due to BPO can be treated safely with a combination of ketoconazole and tamsulosin to get a better success rate of TWOC.
INTRODUCTION
Acute urinary retention (AUR) is one of the most important complications of BPH but its etiology is poorly understood. Prostate infection, bladder over-distension, excessive fluid intake, sexual activity, alcohol consumption and prostatic infarction have all been mentioned but not completely accepted. [1] [2] [3] In addition, there is good evidence that AUR can result from a sudden increase in the sympathetic stimulation with a subsequent increase in the smooth muscle tone of the lower urinary tract. This theory is supported by the beneficial effect of alpha blockers in these cases. 1, 4, 5 Clinically, there are two categories of AUR in cases of BPH that include the spontaneous and the precipitated types. The precipitated retention is referred to the retention triggered by a specific event such as anal surgery, or recent ingestion of some medications as sympathomimetic or anticholinergic drugs. 6 However, in all cases, the first line of treatment involves the immediate insertion of a urethral catheter to relive the pain and to rest the bladder wall. Meanwhile, alpha blockers were found to increase significantly the number of patients who can void satisfactorily after removal of the catheter. 4, 5 Ketoconazole is a synthetic antifungal that has been used since the 1970s. It is an imidazole derivative that is found to be able to block both gonadal and adrenal testosterone synthesis through inhibition of a cytochrome P-450-mediated steroid hydroxylation step, namely that involved the C17-20 lyase. 7, 8 After oral administration of 400 or 600 mg ketoconazole in healthy men, significant reduction of serum testosterone levels occurs within 2 h and nadir testosterone levels are achieved within 8 h. Meanwhile, this inhibitory effect is completely reversible and testosterone levels return to normal within 24 h after cessation of this drug. 9, 10 It has been shown before that, a critical level of androgen is required to maintain the prostatic growth and androgen deprivation usually results in a significant involution of its glandular epithelial component. 11 Therefore, antiandrogens and 5a-reductase inhibitors were effective in treating patients with prostate cancer and BPH, respectively. Given the prompt and efficient antiandrogenic properties of ketoconazole, it has been used successfully in cases of metastatic prostatic carcinoma with impending neurologic injury and in patients with acute renal failure due to bilateral urethral obstruction secondary to advanced prostatic carcinoma. 12, 13 In addition, it was also effective in decreasing postoperative erections after penile surgery. 14 Similarly, the rapid decline of serum testosterone with ketoconazole might be beneficial in cases of AUR secondary to BPH. Therefore, this study was undertaken to evaluate the effect of the combined use of ketoconazole and tamsulosin after urethral catheterization of patients with AUR due to benign prostatic obstruction (BPO).
MATERIALS AND METHODS
This study was carried out at Tanta University Hospital between July 2009 and October 2012. After approval of our institutional review board, we recruited patients who presented with a first episode of AUR due to BPO and an informed consent was obtained from each one. Patients were managed first with uretheral catheterization and then they were subjected to careful history taking, complete clinical examination, routine laboratory investigations and abdomino-pelvic ultrasound. In each patient, the prostate was assessed by digital rectal examination, serum PSA and transrectal ultrasound. We excluded patients with history of neurological disorders, hepatic (serum albumin o 30 g l -1 or prothrombin activity o 75%) or renal impairment (serum creatinine 4 1.4 mg dl -1 ). In addition, patients with suspicious of prostate cancer, as cases with abnormal prostate in digital rectal examination or high PSA (above the normal for age), and those with any concomitant bladder or urethral diseases were also excluded.
After urethral catheterization, the selected patients were randomized through a computer-generated block randomization into two equal groups. The first group received tamsulosin 0.4 mg o.d. plus ketoconazole 200 mg t.d.s. while the second one had tamsulosin in the previous dosage and a placebo for ketoconazole. The placebo was prepared in our local pharmacy at Tanta University Hospital. Tamsulosin was administered after breakfast and ketoconazole, or its placebo, was taken on empty stomach (between meals) with acidic drink, as acidic pH is needed for optimal absorption. In addition, all patients were instructed to avoid antacids for at least 2 h after intake of ketoconazole or its placebo. Both of patients and physicians were blinded to the medications given.
The urethral catheter was kept in place and the drugs were maintained for 7 days. Liver function tests and complete blood count were repeated for all participants at the end of this treatment period and toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (CTCAE, US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, USA). In addition, prostate size was reassessed by transrectal ultrasound at this time. Patients were then put on trial without catheter (TWOC) and those who voided successfully were further evaluated with peak flow rate (PFR) with estimation of the voided volume and the post-void residual urine volume (PVRV; by abdominal ultrasound). Patients with successful TWOC were maintained on a daily tamsulosin (0.4 mg) and finasteride (5 mg) and were seen again in 2 and 4 weeks times to assess the durability of our results.
STATISTICAL ANALYSIS (i) Sample size determination was done according to the following equation 15 :
Where: * m is the sample size required per group at the two sided 5% significance level and 80% power. * p A ¼ 0.8 and it represents the expected proportion of patients with successful TWOC after combined treatment. * p B ¼ 0.55 and it represents the expected proportion of patients with successful TWOC after tamsulosin and placebo.
The previous equation indicated that the number of patients in each group should be X 53.
(ii) The number needed to treat (NNT) was also calculated by the following equation to determine the effectiveness of addition of ketoconazole to tamsulosin in reduction of the failure rate of TWOC:
Where P B is the proportion of patients with failed TWOC in the control group.
And P A is the proportion of patients with failed TWOC in the treatment group.
(iii) The data were collected and analyzed by the Student's t-test, Pearson w 2 test or Spearman's correlation test as appropriate with P o0.05 considered statistically significant. All these tests were done by the computer software SPSS 17.0 for Windows (Chicago, IL, USA).
RESULTS
The study included 106 patients and the two groups were comparable regarding the age, prostate size and retention volume ( Table 1 ). The prostate size ranged from 38 to 93 g and some of our patients were found to be maintained on alpha blockers alone or in combination with finasteride for 2-6 months (Table 1) . In both groups, the administered drugs (tamsulosin and ketoconazole) were well tolerated by the patients with no serious side effects and no patient discontinued the prescribed medications ( Figure 1 ). There was only some gastrointestinal upset (nausea and/or vomiting, grades 1-2 according to CTCAE) in six cases (11.3%) with ketoconazole but we did not report any change in the complete blood count or liver function tests in the follow-up studies (Table 2 ). In addition, we did not receive any specific complains about de novo erectile dysfunction after removal of the catheter in both groups.
After a week of treatment, the transrectal ultrasound revealed that the mean prostate size in tamsulosin group (60.8 ± 14.01 g) was nearly the same as that of the baseline (60.9±14.1 g) with no significant difference (P40.05) between the two results. On the other hand, in the combined treatment group the mean prostate size just before TWOC (61.7±14.8 g) was slightly lower than that of the baseline (62.4±15.2) with a reduction of about 1.12% of the initial size but this difference was found to be statistically significant (Po0.001).
Following removal of the urethral catheter, 41 patients in the combined treatment group (77.35%) were able to void The use of ketoconazole in acute urinary retention M Elbendary et al successfully, whereas, only 58.84% of tamsulosin group were able to do so and this difference was statistically significant (Po0.05) (Table 3 ). However, no correlation was detected between the initial prostate size and the success rate in both groups (P ¼ 0.25 and 0.2, respectively). On the other hand, the mean PFR and the PVRV of the cases with successful TWOC were 10.6±2.5 and 87.4 ± 14.2 ml in the combined treatment group. The corresponding figures in the other group were 12.5 ± 1.98 and 74.2 ± 15.5 ml and the difference between the two groups was found to be statistically significant for each of the two parameters (Po0.05) ( Table 3) . We have also noticed that none of our patients in both groups who showed a successful TWOC had a new episode of urinary retention in the following month. Finally, our statistical analysis showed that the NNT for this combined treatment was 11.75.
DISCUSSION
In this project, we aimed to study the effect of the use of tamsulosin in combination with ketoconazole in patients with AUR secondary to BPH. Despite the fact that, this indication was not reported before for ketoconazole; we assumed that it may be beneficial in these cases. This assumption was related partially to the rapid and efficient antiandrogenic properties of ketoconazole and partially to the prostate itself as it is an androgen-dependent organ. 9, 10 In addition, there is some evidence in the literature that androgen receptor levels may be even higher in the hyperplastic tissue compared with the normal one. 16 On the other hand, we did not use a double placebo control group in this trial since alpha blockers are routinely used in this setting.
The pathophysiology of AUR involves a sudden increase in the bladder outlet obstruction with subsequent detrosur failure. Therefore, tamsulosin and other alpha blockers were successful in improving the results of TWOC in these cases. 4, 5 However, these drugs can only affect the dynamic component of this obstruction but they have nothing to do with its static portion. On the other hand, theoretically, the sharp decline in testosterone level secondary to ketoconazole administration can lead to some decrease in the vascularity and edema of the prostate as well as some involution of its epithelial cells with subsequent improvement of the static component of the acute obstruction. These assumptions can be supported by the well-known effect of androgen deprivation on the prostatic epithelial tissue 11 and by the slight decrease in the prostate size that was reported in this study after ketoconazole administration. In addition, it was shown before that the reduction in DHT due to finasteride administration before TURP can decrease the perioperative bleeding because of the associated decrease in vascularity of this gland. 17, 18 Moreover, in an experimental study in rats it was shown that castration results in a 45% reduction of the blood flow to the prostate after 24 h with a significant increase in apoptosis in both endothelial and stromal cells and the authors suggested that, these changes can directly affect the prostate size. 19 On the other hand, it was demonstrated before that androgen deprivation in animals can also lead to downregulation of the a1a-receptors in the prostate as well as some decrease in their sensitivity. 20 It has been previously noted that the age X70 years, prostate size X50 g, drained volume at catheterization X1000 ml and spontaneous AUR favor TWOC failure. 21 Therefore, we stratified our patients according to these parameters but the two groups were found to be comparable in these regards. On the other hand, although the presence of AUR or even a big prostate alone can be associated with some elevation of the serum PSA, we excluded all patients with high PSA to avoid inclusion of any suspicious cases of prostate cancer. [22] [23] [24] In addition, we have to admit that, the optimum duration of the urethral catheter in cases of AUR due to BPO is still controversial. In a study by Djavan et al. 25 , the authors concluded that it is better to keep the catheter for 7 days to increase the success rate of TWOC. Meanwhile, other studies revealed that some clinicians keep the catheter for 47 days. 26, 27 On the contrary, in a study by Fitzpatrick et al. 21 the authors showed that catheterization 43 days does not influence TWOC success but it is associated with increased rates of adverse events as lower urinary tract infection and hematurea. In the current trial, we kept the catheter for 7 days to give a better chance for ketoconazole to show its effect.
The success rate of TWOC in patients receiving tamsulosin alone in our study (58.8%) was comparable to that reported before by Lucas et al. 5 (53%) and Hua et al. 28 (61%). However, with the combined use of ketoconazole and tamsulosin in the current The use of ketoconazole in acute urinary retention M Elbendary et al project, the success rate of TWOC increased significantly to reach 77.4%. Furthermore, our statistical analysis revealed that the addition of ketoconazole to tamsulosin was helpful to some extent in reduction of the failure rate after TWOC as the NNT for this combined treatment was found to be 11.75. However, we have to put in consideration that we did not use a double placebo control group in this study. Meanwhile, we also observed a significant improvement in each of the voided volume, PFR and PVRV in patients with successful TWOC after the use of ketoconazole. Nevertheless, it is important to note that, the presence of this statistical significance does not necessarily indicate the presence of a clinical significance. On the other hand, it is noteworthy to demonstrate that the patients who get a successful TWOC after ketoconazole administration should be maintained on an alpha blocker and a 5a-reductase inhibitor to decrease the incidence of repeated urinary retention in the future. In this series, we did not report any serious complications secondary to ketoconazole administration. This finding was found to be in agreement to the results of Evans et al.
14 who used 400 mg of ketoconazole t.d.s. to prevent nocturnal erections after penile surgery. In addition, because of the low dose and the short duration of ketoconazole intake in our project, there was no need for any cortisone replacement therapy. Furthermore, the absence of new episodes of urinary retention during the first month after successful TWOC in the ketoconazole group suggests the durability of our results. However, although ketoconazole is a potentially toxic drug and in the field of oncology, it is usually reserved for castration-resistant prostate cancer, it has been shown before that it can be used safely in other benign conditions such as postoperative suppression of nocturnal erection after penile surgery, high-flow priapism, Cushing's disease and alopecia. In these cases, the drug should be used only in well selected cases and it is usually used for a short period and in a low dose. 14, [29] [30] [31] [32] Meanwhile, it is worth mentioning that, the recent advances in the minimally invasive definitive surgical management of BPH have markedly reduced the morbidity of this operation; therefore, the patient with failed TWOC can be easily managed and the use of ketoconazole cannot be justified in this setting if the patient is at any increased risk of its complications.
Finally, the main limitations of this study are the absence of the double placebo control group and the lack of data about the changes in each of the testosterone level and the histopathological findings after ketoconazole administration.
CONCLUSIONS
This preliminary study showed that the use of tamsulosin in combination with ketoconazole might be better than tamsulosin alone in improving the success rate of TWOC in cases of AUR secondary to BPO. Meanwhile, this combined therapy was well tolerated by our selected patients with no major side effects. However, more studies are warranted to identify the best duration of this treatment and to recruit a larger number of patients before the final conclusion. Nausea, n (%) 6 (11.3%) 0 (0%) Vomiting, n (%) 4 (7.5%) 0 (0%) Liver toxicity, n (%) 0 (0%) 0 (0%) Neutropenia, n (%) 0 (0%) 0 (0%) Anemia, n (%) 0 (0%) 0 (0%)
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